Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management

Identifieur interne : 001380 ( Main/Exploration ); précédent : 001379; suivant : 001381

Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management

Auteurs : Noble Kuntworbe [Nouvelle-Zélande] ; Nataly Martini [Nouvelle-Zélande] ; John Shaw [Nouvelle-Zélande] ; Raida Al-Kassas [Nouvelle-Zélande]

Source :

RBID : ISTEX:F34F640C67CCA869CCDC68D98FE0A406A3673694

English descriptors

Abstract

Strategy, Management and Health Policy Enabling Technology, Genomics, Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Postmarketing Phase IV In order to better understand the persistence of malaria, it is timely to reflect on the various approaches toward its eradication and to consider what is being done well and to identify what needs to be improved. This review explores currently available tools and policies designed to eradicate malaria and the potential difficulties associated with each. We have also considered pharmaceutical nanotechnology as a possible tool in the fight against malaria. Each policy, ranging from the adaption of combination drug therapy to the deployment of insecticide‐treated nets was considered to be laudable. The implementation and coverage of policies, however, exposed many gaps with persistence of the disease. Some of the challenges identified include misdiagnosis, production and distribution of fake and substandard antimalarial drugs, misapplication of insecticides, poor infrastructure, lack of sociopolitical will, and conflicts leading to displacement of people. Failure of malaria eradication has been attributed to the development of multiple drug resistance and the side effects associated with the use of conventional antimalarial chemotherapy. The review identified nanotechnology as a formulation strategy that has the potential to improve the safety and efficacy of drug therapy and help the cause of malaria eradication. In conclusion, this review is expected to provide a better understanding of the policies on malaria eradication and challenges associated with each of them. It also suggests that nanotechnology has the potential to reduce side effects of antimalarial drugs and improve their efficacy and should be given serious attention.

Url:
DOI: 10.1002/ddr.21010


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management</title>
<author>
<name sortKey="Kuntworbe, Noble" sort="Kuntworbe, Noble" uniqKey="Kuntworbe N" first="Noble" last="Kuntworbe">Noble Kuntworbe</name>
</author>
<author>
<name sortKey="Martini, Nataly" sort="Martini, Nataly" uniqKey="Martini N" first="Nataly" last="Martini">Nataly Martini</name>
</author>
<author>
<name sortKey="Shaw, John" sort="Shaw, John" uniqKey="Shaw J" first="John" last="Shaw">John Shaw</name>
</author>
<author>
<name sortKey="Al Assas, Raida" sort="Al Assas, Raida" uniqKey="Al Assas R" first="Raida" last="Al-Kassas">Raida Al-Kassas</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F34F640C67CCA869CCDC68D98FE0A406A3673694</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1002/ddr.21010</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-F41KCNRX-G/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000711</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000711</idno>
<idno type="wicri:Area/Istex/Curation">000711</idno>
<idno type="wicri:Area/Istex/Checkpoint">000389</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000389</idno>
<idno type="wicri:doubleKey">0272-4391:2012:Kuntworbe N:malaria:intervention:policies</idno>
<idno type="wicri:Area/Main/Merge">001381</idno>
<idno type="wicri:Area/Main/Curation">001380</idno>
<idno type="wicri:Area/Main/Exploration">001380</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management</title>
<author>
<name sortKey="Kuntworbe, Noble" sort="Kuntworbe, Noble" uniqKey="Kuntworbe N" first="Noble" last="Kuntworbe">Noble Kuntworbe</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland</wicri:regionArea>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Martini, Nataly" sort="Martini, Nataly" uniqKey="Martini N" first="Nataly" last="Martini">Nataly Martini</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland</wicri:regionArea>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Shaw, John" sort="Shaw, John" uniqKey="Shaw J" first="John" last="Shaw">John Shaw</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland</wicri:regionArea>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Al Assas, Raida" sort="Al Assas, Raida" uniqKey="Al Assas R" first="Raida" last="Al-Kassas">Raida Al-Kassas</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland</wicri:regionArea>
<wicri:noRegion>Auckland</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Nouvelle-Zélande</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Drug Development Research</title>
<title level="j" type="alt">DRUG DEVELOPMENT RESEARCH</title>
<idno type="ISSN">0272-4391</idno>
<idno type="eISSN">1098-2299</idno>
<imprint>
<biblScope unit="vol">73</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="167">167</biblScope>
<biblScope unit="page" to="184">184</biblScope>
<biblScope unit="page-count">18</biblScope>
<date type="published" when="2012-06">2012-06</date>
</imprint>
<idno type="ISSN">0272-4391</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0272-4391</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>African children</term>
<term>African countries</term>
<term>Amide groups</term>
<term>Anticancer agents</term>
<term>Antimalarial</term>
<term>Antimalarial activity</term>
<term>Antimalarial compounds</term>
<term>Antimalarial drug formulation</term>
<term>Antimalarial drug formulations</term>
<term>Antimalarial drugs</term>
<term>Antimalarial formulations</term>
<term>Artemether</term>
<term>Available tools</term>
<term>Basic molecules</term>
<term>Bioactive</term>
<term>Blood cells</term>
<term>Burkina faso</term>
<term>Cellular uptake</term>
<term>Central core</term>
<term>Chemotherapeutic agents</term>
<term>Chitosan</term>
<term>Chitosan nanoparticles</term>
<term>Chloroquine</term>
<term>Chloroquine phosphate</term>
<term>Clin microbiol</term>
<term>Clinical algorithm</term>
<term>Clinical diagnosis</term>
<term>Clinical signs</term>
<term>Colloid interface</term>
<term>Colloidal particles</term>
<term>Colloids surf</term>
<term>Combination therapies</term>
<term>Combination therapy</term>
<term>Continuous phase</term>
<term>Conventional counterparts</term>
<term>Conventional dosage forms</term>
<term>Conventional formulations</term>
<term>Conventional nanocarriers</term>
<term>Cosmetic products</term>
<term>Deliv</term>
<term>Dendrimers</term>
<term>Divergent approach</term>
<term>Dosage</term>
<term>Dosage form</term>
<term>Dosage forms</term>
<term>Double desolvation</term>
<term>Drug</term>
<term>Drug deliv</term>
<term>Drug delivery</term>
<term>Drug loading</term>
<term>Drug release</term>
<term>Economic reasons</term>
<term>Emulsifying agent</term>
<term>Emulsion</term>
<term>Endemic</term>
<term>Endemic areas</term>
<term>Endemic malaria</term>
<term>Enzyme replacement therapy</term>
<term>Erythrocyte</term>
<term>Falciparum</term>
<term>Formulation</term>
<term>Formulation strategy</term>
<term>Free drug</term>
<term>Gelatin</term>
<term>Gelatin nanoparticles</term>
<term>Gene transfection</term>
<term>General population</term>
<term>Good stability</term>
<term>Halofantrine</term>
<term>Health care</term>
<term>Health sciences</term>
<term>Hemolytic side effects</term>
<term>High coverage</term>
<term>High humidity</term>
<term>Interfacial polyaddition</term>
<term>Intravenous administration</term>
<term>Ionotropic gelation</term>
<term>Itns</term>
<term>Kuntworbe</term>
<term>Laboratory diagnosis</term>
<term>Laboratory mosquitoes</term>
<term>Lipid</term>
<term>Liposomal</term>
<term>Liposomal formulations</term>
<term>Liposome</term>
<term>Malar</term>
<term>Malaria</term>
<term>Malaria control</term>
<term>Malaria diagnosis</term>
<term>Malaria eradication</term>
<term>Malaria management</term>
<term>Malaria microscopy</term>
<term>Malaria parasites</term>
<term>Malaria policies</term>
<term>Malaria transmission</term>
<term>Malaria treatment</term>
<term>Malarial topoisomerase</term>
<term>Many years</term>
<term>Monotherapy</term>
<term>Mosqueira</term>
<term>Mosquito</term>
<term>Mosquito vector</term>
<term>Nanocapsules</term>
<term>Nanoemulsions</term>
<term>Nanoparticles</term>
<term>Nanotechnology</term>
<term>Newer approaches</term>
<term>Nonaffected erythrocytes</term>
<term>Northern ghana</term>
<term>Novel applications</term>
<term>Oral administration</term>
<term>Oral bioavailability</term>
<term>Oral dosage forms</term>
<term>Other hand</term>
<term>Pamam</term>
<term>Pamam dendrimers</term>
<term>Parasite</term>
<term>Parenteral</term>
<term>Parenteral administration</term>
<term>Parenteral delivery</term>
<term>Particular dosage form</term>
<term>Pharm</term>
<term>Pharmaceutical</term>
<term>Pharmaceutical nanoparticles</term>
<term>Pharmaceutical nanotechnology</term>
<term>Plasmodium</term>
<term>Plasmodium falciparum</term>
<term>Plasmodium parasite</term>
<term>Polymer</term>
<term>Pregnant women</term>
<term>Quinine</term>
<term>Raida school</term>
<term>Rapid diagnosis</term>
<term>Rapid dissemination</term>
<term>Reactive oxygen species</term>
<term>Recent advances</term>
<term>Refugee camps</term>
<term>Reticuloendothelial system</term>
<term>Rural areas</term>
<term>Same time</term>
<term>Severe falciparum malaria</term>
<term>Severe malaria</term>
<term>Side effects</term>
<term>Size range</term>
<term>Solid dosage forms</term>
<term>Solution dosage forms</term>
<term>Sterile insect technique</term>
<term>Substandard antimalarial drugs</term>
<term>Successful delivery</term>
<term>Such preparations</term>
<term>Tablet</term>
<term>Target delivery</term>
<term>Thin blood smear</term>
<term>Tight junction opening</term>
<term>Transepithelial transport</term>
<term>Uncomplicated malaria</term>
<term>Vector control measures</term>
<term>West africa</term>
<term>Wiley periodicals</term>
<term>World malaria report</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Strategy, Management and Health Policy Enabling Technology, Genomics, Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Postmarketing Phase IV In order to better understand the persistence of malaria, it is timely to reflect on the various approaches toward its eradication and to consider what is being done well and to identify what needs to be improved. This review explores currently available tools and policies designed to eradicate malaria and the potential difficulties associated with each. We have also considered pharmaceutical nanotechnology as a possible tool in the fight against malaria. Each policy, ranging from the adaption of combination drug therapy to the deployment of insecticide‐treated nets was considered to be laudable. The implementation and coverage of policies, however, exposed many gaps with persistence of the disease. Some of the challenges identified include misdiagnosis, production and distribution of fake and substandard antimalarial drugs, misapplication of insecticides, poor infrastructure, lack of sociopolitical will, and conflicts leading to displacement of people. Failure of malaria eradication has been attributed to the development of multiple drug resistance and the side effects associated with the use of conventional antimalarial chemotherapy. The review identified nanotechnology as a formulation strategy that has the potential to improve the safety and efficacy of drug therapy and help the cause of malaria eradication. In conclusion, this review is expected to provide a better understanding of the policies on malaria eradication and challenges associated with each of them. It also suggests that nanotechnology has the potential to reduce side effects of antimalarial drugs and improve their efficacy and should be given serious attention.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Nouvelle-Zélande</li>
</country>
</list>
<tree>
<country name="Nouvelle-Zélande">
<noRegion>
<name sortKey="Kuntworbe, Noble" sort="Kuntworbe, Noble" uniqKey="Kuntworbe N" first="Noble" last="Kuntworbe">Noble Kuntworbe</name>
</noRegion>
<name sortKey="Al Assas, Raida" sort="Al Assas, Raida" uniqKey="Al Assas R" first="Raida" last="Al-Kassas">Raida Al-Kassas</name>
<name sortKey="Al Assas, Raida" sort="Al Assas, Raida" uniqKey="Al Assas R" first="Raida" last="Al-Kassas">Raida Al-Kassas</name>
<name sortKey="Martini, Nataly" sort="Martini, Nataly" uniqKey="Martini N" first="Nataly" last="Martini">Nataly Martini</name>
<name sortKey="Shaw, John" sort="Shaw, John" uniqKey="Shaw J" first="John" last="Shaw">John Shaw</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001380 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001380 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F34F640C67CCA869CCDC68D98FE0A406A3673694
   |texte=   Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021